Okay so it isn't the cure to cancer we all hoped for. How you were able to read that new release and get nothing from it astounds me. He basically touched on nearly all the concerns that people were exploding about on the forums. It didn't reach certain endpoints they had anticipated, but it did reach other ones. Then clarification is given regarding how secondary endpoints can be used as the new primary endpoint in the trials. At least it seems to reduce time on ventilators and reduce chances of having to go onto one. Better than anything else we see currently approved on the market from what I've seen
News 
Market Data 
Discover 
